Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 17;12(4):1588.
doi: 10.3390/jcm12041588.

Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis

Wanyi Sun  1 , Yun Wu  2 , Fei Ma  2 , Jinhu Fan  1 , Youlin Qiao  1   3
Affiliations
Review

Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis

Wanyi Sun et al. J Clin Med. .

Abstract

The optimal treatment regimen for breast cancer patients with gBRCA mutations remains controversial given the availability of numerous options, such as platinum-based agents, polymerase inhibitors (PARPis), and other agents. We included phase II or III RCTs and estimated the HR with 95% CI for OS, PFS, and DFS, in addition to the OR with 95% CI for ORR and pCR. We determined the treatment arm rankings by P-scores. Furthermore, we carried out a subgroup analysis in TNBC and HR-positive patients. We conducted this network meta-analysis using R 4.2.0 and a random-effects model. A total of 22 RCTs were eligible, involving 4253 patients. In the pairwise comparisons, PARPi + Platinum + Chemo was better than PARPi + Chemo for OS (in whole study group and in both subgroups) as well as PFS. The ranking tests demonstrated that PARPi + Platinum + Chemo ranked first in PFS, DFS, and ORR. Platinum + Chemo showed higher OS than PARPi + Chemo. The ranking tests for PFS, DFS, and pCR indicated that, except for the best treatment (PARPi + Platinum + Chemo) containing PARPi, the second and third treatments were platinum monotherapy or platinum-based chemotherapy. In conclusion, PARPi + Platinum + Chemo might be the best regime for gBRCA-mutated BC. Platinum drugs showed more favorable efficacy than PARPi in both combination and monotherapy.

Keywords: BRCA-mutated HER2-negative breast cancer; efficacy; immunotherapy; network meta-analysis; platinum; polymerase inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of the article selection process.
Figure 2
Figure 2
Network structure diagram according to different outcomes. Abbreviations: PARPi for PARP inhibitor, Bev for bevacizumab, Atezo for atezolizumab, Chemo for chemotherapy.
Figure 2
Figure 2
Network structure diagram according to different outcomes. Abbreviations: PARPi for PARP inhibitor, Bev for bevacizumab, Atezo for atezolizumab, Chemo for chemotherapy.
Figure 3
Figure 3
Forest map of main results (in comparison with chemotherapy). Abbreviations: PARPi for PARP inhibitor, Bev for bevacizumab, Atezo for atezolizumab, Chemo for chemotherapy.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. John E.M., Miron A., Gong G., Phipps A.I., Felberg A., Li F.P., West D.W., Whittemore A.S. Prevalence of Pathogenic BRCA1 Mutation Carriers in 5 US Racial/Ethnic Groups. JAMA. 2007;298:2869–2876. doi: 10.1001/jama.298.24.2869. - DOI - PubMed
    1. Malone K.E., Daling J.R., Doody D.R., Hsu L., Bernstein L., Coates R.J., Marchbanks P.A., Simon M.S., McDonald J.A., Norman S.A., et al. Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years. Cancer Res. 2006;66:8297–8308. doi: 10.1158/0008-5472.CAN-06-0503. - DOI - PubMed
    1. Neiger H., Siegler E., Shi Y. Breast Cancer Predisposition Genes and Synthetic Lethality. Int. J. Mol. Sci. 2021;22:5614. doi: 10.3390/ijms22115614. - DOI - PMC - PubMed
    1. Zhang D., Baldwin P., Leal A.S.M., Carapellucci S., Sridhar S., Liby K.T. A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice. Theranostics. 2019;9:6224–6238. doi: 10.7150/thno.36281. - DOI - PMC - PubMed